Strategic Alliance: BIEL + Viant + VLMS
Opening the Door to Vertex, Hinge Health, Medtronic—and a New Era in Non-Opioid Pain Care
BIEL’s revival unlocks public market leverage
Viant and VLMS join as strategic equity partners
Alliance creates a full-spectrum pain care platform
PPS arbitrage and tax efficiency offer asymmetric upside
Positioned for partnerships with Vertex, Hinge Health, and Medtronic
The Alliance Framework
BioElectronics (BIEL): FDA-cleared wearable therapy (ActiPatch, RecoveryRx)
Viant Medical: Smart device engineering, scalable production, regulatory acceleration
VLMS Global: App development, CMS coding, AI billing, retail distribution, reimbursement scaling
Sree Koneru (Viant) and Keith Nalepka (VLMS) both previously held executive roles at BIEL
Equity Partnership Model
Viant and VLMS each taking a 1B share position (@.0002 - hello Jimzin) could yield $9.8M profit if PPS reaches $0.01 - EASIEST MONEY THEY WILL EVER MAKE!
BIEL’s $40M tax-loss carryforward shields early profits from taxation (which Viant, VLMS and all shareholders/equity stakeholders benefit from)
Public market access achieved instantly—no IPO or SPAC required
The Equity Windfall Engine
Viant and VLMS maintain a fixed cost basis while PPS climbs
Each milestone (FDA expansion, reimbursement, retail adoption) multiplies equity value
Balance sheets transform with every PPS uptick
Equity becomes a high-leverage asset with minimal tax exposure
Opening the Door - Strategic Fit with Vertex, Hinge Health & Medtronic
Vertex’s Journavx complements BIEL’s chronic/post-op solution
Hinge Health benefits from hardware, data, and reimbursement engine
Medtronic could integrate BIEL’s wearable tech into its neuromodulation portfolio
Milestones That Could Transform PPS
$400K in quarterly revenue could push PPS to $0.01
$10M in annual profit (with VA adoption and RecoveryRx Vet) could push PPS to $0.04
Full U.S. insurance reimbursement could elevate PPS to $0.25–$0.40
Strategic Execution Plan
Launch ActiPatch base model for volume
Introduce ActiPatch+ with smart features at premium pricing
Co-branded “Recovery Kits” with Journavx and Hinge PT for post-op care
Employer MSK bundles offered via Hinge Health
VLMS drives retail and reimbursement via Walgreens, CVS, and hospital networks
Medtronic integration enables broader clinical adoption
BIEL as a Ground-Floor Opportunity
Current PPS: $0.0001–$0.0002
Open-market accumulation allows up to 5% of shares to be acquired instantly
No regulatory hurdles for equity acquisition
FDA-cleared products: ActiPatch®, RecoveryRx®, RecoveryRx Vet®
Mechanism: PRFE / PSWT
Scientific validation: Nature-published study
Viant & VLMS Arbitrage Playbook
Viant and VLMS evolve into hybrid operating-investment entities
Financial strength fuels BIEL’s growth
Long-term CAGR outpaces cost of capital
PPS-linked upside eclipses traditional margins
Equity arbitrage becomes a balance sheet weapon
The Path Forward
BIEL + Viant + VLMS = Engine
Vertex, Hinge Health, Medtronic = Accelerators
Equity acquisition + platform adoption = Profit windfall
The door is open to redefine pain care for millions
Opening the Door to Vertex, Hinge Health, Medtronic—and a New Era in Non-Opioid Pain Care
BIEL’s revival unlocks public market leverage
Viant and VLMS join as strategic equity partners
Alliance creates a full-spectrum pain care platform
PPS arbitrage and tax efficiency offer asymmetric upside
Positioned for partnerships with Vertex, Hinge Health, and Medtronic
The Alliance Framework
BioElectronics (BIEL): FDA-cleared wearable therapy (ActiPatch, RecoveryRx)
Viant Medical: Smart device engineering, scalable production, regulatory acceleration
VLMS Global: App development, CMS coding, AI billing, retail distribution, reimbursement scaling
Sree Koneru (Viant) and Keith Nalepka (VLMS) both previously held executive roles at BIEL
Equity Partnership Model
Viant and VLMS each taking a 1B share position (@.0002 - hello Jimzin) could yield $9.8M profit if PPS reaches $0.01 - EASIEST MONEY THEY WILL EVER MAKE!
BIEL’s $40M tax-loss carryforward shields early profits from taxation (which Viant, VLMS and all shareholders/equity stakeholders benefit from)
Public market access achieved instantly—no IPO or SPAC required
The Equity Windfall Engine
Viant and VLMS maintain a fixed cost basis while PPS climbs
Each milestone (FDA expansion, reimbursement, retail adoption) multiplies equity value
Balance sheets transform with every PPS uptick
Equity becomes a high-leverage asset with minimal tax exposure
Opening the Door - Strategic Fit with Vertex, Hinge Health & Medtronic
Vertex’s Journavx complements BIEL’s chronic/post-op solution
Hinge Health benefits from hardware, data, and reimbursement engine
Medtronic could integrate BIEL’s wearable tech into its neuromodulation portfolio
Milestones That Could Transform PPS
$400K in quarterly revenue could push PPS to $0.01
$10M in annual profit (with VA adoption and RecoveryRx Vet) could push PPS to $0.04
Full U.S. insurance reimbursement could elevate PPS to $0.25–$0.40
Strategic Execution Plan
Launch ActiPatch base model for volume
Introduce ActiPatch+ with smart features at premium pricing
Co-branded “Recovery Kits” with Journavx and Hinge PT for post-op care
Employer MSK bundles offered via Hinge Health
VLMS drives retail and reimbursement via Walgreens, CVS, and hospital networks
Medtronic integration enables broader clinical adoption
BIEL as a Ground-Floor Opportunity
Current PPS: $0.0001–$0.0002
Open-market accumulation allows up to 5% of shares to be acquired instantly
No regulatory hurdles for equity acquisition
FDA-cleared products: ActiPatch®, RecoveryRx®, RecoveryRx Vet®
Mechanism: PRFE / PSWT
Scientific validation: Nature-published study
Viant & VLMS Arbitrage Playbook
Viant and VLMS evolve into hybrid operating-investment entities
Financial strength fuels BIEL’s growth
Long-term CAGR outpaces cost of capital
PPS-linked upside eclipses traditional margins
Equity arbitrage becomes a balance sheet weapon
The Path Forward
BIEL + Viant + VLMS = Engine
Vertex, Hinge Health, Medtronic = Accelerators
Equity acquisition + platform adoption = Profit windfall
The door is open to redefine pain care for millions
1
